{"product_id":"bladder-cancer-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape","title":"Bladder Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape","description":"\u003cp\u003eBladder Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape\u003c\/p\u003e\n\n\u003cp\u003eSummary\u003c\/p\u003e\n\n\u003cp\u003eThis reports provides a data-driven overview of the current and future competitive landscape in bladder cancer therapeutics.\u003c\/p\u003e\n\n\u003cp\u003eSynopsisIn 2022, there will be more than 460,000 diagnosed incident cases of bladder cancer across 16 pharmaceutical markets.There are a good number of marketed innovator drugs for the treatment of bladder cancer, mostly checkpoint inhibitors.The bladder cancer pipeline consists of three products in pre-registration and 30 products in Phase III development.Commercial sponsors dominate clinical trial development in bladder cancer, with the US emerging as the key country for conducting Phase III trials.During the past 12 months, six strategic alliances and two merger and acquisition transactions involving bladder cancer assets were successfully completed.Regulatory decisions are expected soon for key innovator molecules from ImmunityBio and Ferring Pharmaceuticals.Scope\u003c\/p\u003e\n\n\u003cp\u003eGlobalData’s bladder cancer: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.\u003c\/p\u003e \n\n\u003cp\u003eComponents of the report include - Disease LandscapeDisease OverviewEpidemiology OverviewTreatment OverviewMarketed Products AssessmentBreakdown by Mechanism of Action, Molecule Type, Route of AdministrationProduct Profiles with Sales ForecastPricing and Reimbursement AssessmentRetail or Manufacturer Price of ProductsTime to Pricing and Time to ReimbursementPipeline AssessmentBreakdown by Development Stage, Mechanism of Action, Molecule Type, Route of AdministrationProduct Profiles with Sales ForecastLate-to-mid-stage Pipeline DrugsPhase Transition Success Rate and Likelihood of ApprovalClinical Trials AssessmentBreakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint StatusEnrolment Analytics, Site Analytics, Feasibility AnalysisDeals LandscapeMergers, Acquisitions, and Strategic Alliances by RegionOverview of Recent DealsCommercial AssessmentKey Market PlayersFuture Market CatalystsReasons to BuyDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.Develop business strategies by understanding the trends shaping and driving the bladder cancer market.Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer market in the future.Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 97 Pages \/ MCW16225958","offer_id":47640100405554,"sku":null,"price":4194.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/bladder-cancer-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}